WATERTOWN, Mass. and STOCKHOLM, Sweden, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI), today announced topline ...
WATERTOWN, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by ...
The Phase 3 program for SEL-212 was run by Selecta and funded by Sobi. Under the terms of the agreement with Sobi, Selecta is eligible to receive additional development and regulatory milestone ...
Selecta Biosciences (NASDAQ:SELB) and Swedish Orphan Biovitrum (Sobi) (OTCPK:BIOVF) said SEL-212 met the main goals of two phase 3 trials to treat adult patients with chronic refractory gout. Gout is ...
- Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta’s breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need ...
STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the ...
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in ...
STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback